The company’s lead drug candidate, AVZO-021, is a novel, highly potent and selective inhibitor of CDK2, a key enzyme involved in cell cycle regulation. As of Q1 2024, AVZO-021 is being studied in a Phase I study in the US for the treatment of advanced solid tumors.